A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function

NCT02399202 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Impairment

Interventions

DRUG: osilodrostat

Sponsor

Novartis Pharmaceuticals